卡那奴单抗。
Canakinumab.
机构信息
Tufts University School of Medicine, Boston, MA, USA.
出版信息
MAbs. 2010 Jan-Feb;2(1):3-13. doi: 10.4161/mabs.2.1.10328. Epub 2010 Jan 15.
Abstract
Canakinumab (ACZ885, Ilaris) is a human anti-IL-1beta monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of IL-1beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, which are inflammatory diseases related to cryopyrin-associated periodic syndromes. The drug is currently being evaluated for its potential in the treatment of rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, chronic obstructive pulmonary disease, type 1 and 2 diabetes and ocular diseases. Reports from clinical trials suggest that canakinumab is well-tolerated in most patients, and no serious adverse effects have been reported. The drug provides significant advantages over existing competitive therapies, including bimonthly administration and approved use in children.
摘要
卡那单抗（ACZ885，依拉利司）是由诺华公司开发的一种人源抗白细胞介素-1β单克隆抗体。其作用机制基于中和白细胞介素-1β信号，从而抑制自身免疫源性疾病患者的炎症。2009 年 6 月，该药物获得美国食品和药物管理局批准，用于治疗家族性冷自身炎症综合征和 Muckle-Wells 综合征，这两种疾病均与 Cryopyrin 相关周期性综合征有关。该药物目前正在评估其在治疗类风湿关节炎、全身型幼年特发性关节炎、慢性阻塞性肺疾病、1 型和 2 型糖尿病以及眼部疾病方面的潜力。临床试验报告表明，卡那单抗在大多数患者中耐受性良好，且未报告严重不良反应。与现有的竞争性治疗方法相比，该药物具有显著优势，包括每两个月给药一次以及在儿童中获批使用。
相似文献
1
Canakinumab.卡那奴单抗。
MAbs. 2010 Jan-Feb;2(1):3-13. doi: 10.4161/mabs.2.1.10328. Epub 2010 Jan 15.
2
Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.卡那奴单抗：一种人源抗 IL-1β 单克隆抗体，用于治疗 Cryopyrin 相关周期性综合征。
Expert Rev Clin Immunol. 2010 Nov;6(6):831-41. doi: 10.1586/eci.10.66.
3
[An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].[针对冷吡啉相关周期性综合征（CAPS）患者的治疗方法：一种新型生物反应调节剂——卡那单抗]
Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(1):23-9. doi: 10.2177/jsci.35.23.
4
Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).卡那奴单抗（ACZ885，一种完全人源 IgG1 抗 IL-1β mAb）可诱导 Cryopyrin 相关周期性综合征（CAPS）儿科患者的持续缓解。
Arthritis Res Ther. 2011 Feb 28;13(1):R34. doi: 10.1186/ar3266.
5
Canakinumab for the treatment of cryopyrin-associated periodic syndromes.卡那单抗用于治疗冷吡啉相关周期性综合征。
Drugs Today (Barc). 2009 Oct;45(10):731-5.
6
Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.卡那单抗的药代动力学和药效学特性，一种人源抗白细胞介素-1β 单克隆抗体。
Clin Pharmacokinet. 2012 Jun 1;51(6):e1-18. doi: 10.2165/11599820-000000000-00000.
7
Canakinumab in pediatric rheumatic diseases.卡那单抗在儿童风湿性疾病中的应用
Expert Opin Biol Ther. 2013 Apr;13(4):615-22. doi: 10.1517/14712598.2013.778239. Epub 2013 Mar 4.
8
Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.卡那单抗，一种针对白细胞介素-1β的全人源单克隆抗体，用于炎症性疾病的潜在治疗。
Curr Opin Mol Ther. 2009 Feb;11(1):81-9.
9
[Canakinumab: a promising treatment in rheumatology].[卡那单抗：风湿病学中一种有前景的治疗方法]
Rev Med Suisse. 2012 Jan 11;8(323):57-60.
10
Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome".儿童系统性炎症性疾病的发病机制：“抗细胞因子单克隆抗体治疗川崎病、全身型幼年特发性关节炎及冷吡啉相关周期性发热综合征临床试验的经验教训”
Mod Rheumatol. 2015 Jan;25(1):1-10. doi: 10.3109/14397595.2014.902747. Epub 2014 May 20.
引用本文的文献
1
Immunotherapies for Aging and Age-Related Diseases: Advances, Pitfalls, and Prospects.衰老及与年龄相关疾病的免疫疗法：进展、困境与前景
Research (Wash D C). 2025 Sep 8;8:0866. doi: 10.34133/research.0866. eCollection 2025.
2
Neutrophil extracellular traps and interleukin-1β in cystic fibrosis lung disease.中性粒细胞胞外诱捕网与白细胞介素-1β在囊性纤维化肺病中的作用
Front Immunol. 2025 Jul 28;16:1595994. doi: 10.3389/fimmu.2025.1595994. eCollection 2025.
3
Pharmacological Evaluation of Araliadiol as a Novel Anti-Inflammatory Agent in LPS-Induced RAW 264.7 Cells.刺囊酸作为新型抗炎剂在脂多糖诱导的RAW 264.7细胞中的药理学评价
Biomedicines. 2025 Jun 8;13(6):1408. doi: 10.3390/biomedicines13061408.
4
Identification of progression related LncRNAs in colorectal cancer aggressiveness.结直肠癌侵袭性中与进展相关的长链非编码RNA的鉴定
Sci Rep. 2025 May 18;15(1):17258. doi: 10.1038/s41598-025-02096-7.
5
Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system.阿那白滞素和卡那单抗的上市后安全性：一项基于美国食品药品监督管理局不良事件报告系统的真实世界药物警戒研究。
Front Pharmacol. 2025 Apr 30;16:1483669. doi: 10.3389/fphar.2025.1483669. eCollection 2025.
6
Vaginal Candida albicans infections: host-pathogen-microbiome interactions.阴道白色念珠菌感染：宿主-病原体-微生物组相互作用
FEMS Microbiol Rev. 2025 Jan 14;49. doi: 10.1093/femsre/fuaf013.
7
The context-dependent effect of cellular senescence: From embryogenesis and wound healing to aging.细胞衰老的情境依赖性效应：从胚胎发生、伤口愈合到衰老
Ageing Res Rev. 2025 Jul;109:102760. doi: 10.1016/j.arr.2025.102760. Epub 2025 May 1.
8
NLRP3 inflammasome in neuroinflammation and central nervous system diseases.NLRP3炎性小体在神经炎症和中枢神经系统疾病中的作用
Cell Mol Immunol. 2025 Apr;22(4):341-355. doi: 10.1038/s41423-025-01275-w. Epub 2025 Mar 13.
9
The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells.白细胞介素-1β抑制剂卡那单抗（易来力®）对人骨骼肌细胞中白细胞介素-6产生的影响。
PLoS One. 2025 Mar 6;20(3):e0316110. doi: 10.1371/journal.pone.0316110. eCollection 2025.
10
Discovery and Phase 1 study of a novel monoclonal antibody against human IL-1β for the treatment of IL-1β-mediated diseases.一种用于治疗白细胞介素-1β（IL-1β）介导疾病的新型抗人IL-1β单克隆抗体的发现及1期研究
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf009.
本文引用的文献
1
The modern management of gout.痛风的现代治疗方法。
Rheumatology (Oxford). 2010 Jan;49(1):5-14. doi: 10.1093/rheumatology/kep306. Epub 2009 Oct 5.
2
Gout--current diagnosis and treatment.痛风——当前的诊断与治疗
Dtsch Arztebl Int. 2009 Aug;106(34-35):549-55. doi: 10.3238/arztebl.2009.0549. Epub 2009 Aug 24.
3
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).冷吡啉相关周期性综合征（CAPS）患者的长期管理：聚焦于rilonacept（IL-1 Trap）。
Biologics. 2008 Dec;2(4):733-42. doi: 10.2147/btt.s3167.
4
An autoinflammatory disease due to homozygous deletion of the IL1RN locus.一种由于IL1RN基因座纯合缺失所致的自身炎症性疾病。
N Engl J Med. 2009 Jun 4;360(23):2438-44. doi: 10.1056/NEJMoa0809568.
5
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.一种伴有白细胞介素-1受体拮抗剂缺乏的自身炎症性疾病。
N Engl J Med. 2009 Jun 4;360(23):2426-37. doi: 10.1056/NEJMoa0807865.
6
Use of canakinumab in the cryopyrin-associated periodic syndrome.卡那单抗在冷吡啉相关周期性综合征中的应用。
N Engl J Med. 2009 Jun 4;360(23):2416-25. doi: 10.1056/NEJMoa0810787.
7
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.冷吡啉相关周期性综合征患者体内白细胞介素1β的调节
J Exp Med. 2009 May 11;206(5):1029-36. doi: 10.1084/jem.20082481. Epub 2009 Apr 13.
8
Immunological and inflammatory functions of the interleukin-1 family.白细胞介素-1家族的免疫和炎症功能。
Annu Rev Immunol. 2009;27:519-50. doi: 10.1146/annurev.immunol.021908.132612.
9
The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis.髓样相关蛋白8和14复合物，一种Toll样受体4的新型配体，与白细胞介素-1β在全身型幼年特发性关节炎中形成正反馈机制。
Arthritis Rheum. 2009 Mar;60(3):883-91. doi: 10.1002/art.24349.
10
Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.卡那单抗，一种针对白细胞介素-1β的全人源单克隆抗体，用于炎症性疾病的潜在治疗。
Curr Opin Mol Ther. 2009 Feb;11(1):81-9.
Zotero 插件